Organigram Global (NASDAQ:OGI) Announces Quarterly Earnings Results

Organigram Global (NASDAQ:OGI) posted its quarterly earnings data on Tuesday. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.04), Zacks reports. Organigram Global had a negative net margin of 9.22% and a negative return on equity of 13.41%. The business had revenue of $76.41 million during the quarter, compared to analyst estimates of $68.20 million.

Here are the key takeaways from Organigram Global’s conference call:

• Record financial performance: Q3 net revenue rose 49% year over year to CAD 105.8 million, while adjusted EBITDA reached a record CAD 13.4 million and adjusted gross margin expanded to 37%. Management expects fiscal 2026 revenue to exceed CAD 350 million, with margins and EBITDA meaningfully above fiscal 2025 levels.
• Sanity Group is scaling as planned: The German business contributed €24.5 million of revenue during OrganiGram’s ownership period, and international sales represented roughly 35% of consolidated revenue. Management expects Sanity’s revenue growth to continue, with operating expenses remaining relatively stable and creating further P&L leverage.
• Canadian product recovery is gaining traction: New vape hardware and higher-potency products helped improve vape share in June, while infused pre-rolls returned to growth. Flower share increased to 12.5% year over year, and beverages and concentrates also posted strong gains as the company reduces its SKU count and focuses on higher-performing products.
• International supply and margin opportunities remain significant: OrganiGram is improving Canadian flower pass rates, adding suppliers, and pursuing EU GMP-compliant remediation pathways to meet tight German demand. EU GMP certification could meaningfully improve margins by reducing reliance on European processing, although no approval timeline was provided.
• Cash flow remains a near-term concern: Free cash flow was negative CAD 3.9 million in Q3, and management expects negative free cash flow for fiscal 2026 because of working-capital investments supporting the larger Sanity-led business. Cash and cash equivalents were CAD 11.7 million at quarter end, although total liquidity including debt facilities was CAD 49.2 million.

Organigram Global Stock Up 1.6%

Shares of OGI traded up $0.02 during trading hours on Wednesday, reaching $1.25. 914,756 shares of the company traded hands, compared to its average volume of 801,243. The stock has a market capitalization of $176.22 million, a PE ratio of -9.55 and a beta of 1.46. The stock has a fifty day simple moving average of $0.99 and a 200 day simple moving average of $1.24. Organigram Global has a fifty-two week low of $0.85 and a fifty-two week high of $2.24.

Institutional Trading of Organigram Global

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tidal Investments LLC boosted its holdings in shares of Organigram Global by 4.9% during the second quarter. Tidal Investments LLC now owns 2,646,879 shares of the company’s stock worth $3,573,000 after purchasing an additional 124,356 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Organigram Global by 43.2% in the 4th quarter. Renaissance Technologies LLC now owns 1,405,348 shares of the company’s stock valued at $2,361,000 after buying an additional 423,900 shares during the period. Millennium Management LLC acquired a new stake in shares of Organigram Global during the 4th quarter worth $1,260,000. Goldman Sachs Group Inc. boosted its position in Organigram Global by 82.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 466,585 shares of the company’s stock worth $784,000 after purchasing an additional 210,391 shares during the period. Finally, Two Sigma Investments LP acquired a new position in Organigram Global in the 3rd quarter worth $907,000. 34.63% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (d)” rating on shares of Organigram Global in a research report on Tuesday, June 9th. Wall Street Zen downgraded Organigram Global from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Organigram Global Company Profile

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.